sb 203580 has been researched along with peptide elongation factor 2 in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (peptide elongation factor 2) | Trials (peptide elongation factor 2) | Recent Studies (post-2010) (peptide elongation factor 2) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 790 | 8 | 207 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, P; Haydon, CE; Knebel, A; Morrice, N | 1 |
1 other study(ies) available for sb 203580 and peptide elongation factor 2
| Article | Year |
|---|---|
Stress-induced regulation of eukaryotic elongation factor 2 kinase by SB 203580-sensitive and -insensitive pathways.
Topics: Amino Acid Sequence; Anisomycin; Calcium-Calmodulin-Dependent Protein Kinases; Dose-Response Relationship, Drug; Elongation Factor 2 Kinase; Enzyme Inhibitors; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinase 11; Mitogen-Activated Protein Kinase 13; Mitogen-Activated Protein Kinases; Molecular Sequence Data; p38 Mitogen-Activated Protein Kinases; Peptide Elongation Factor 2; Phosphorylation; Protein Serine-Threonine Kinases; Pyridines; Serine; Signal Transduction; Stress, Physiological; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |